A TWiV trio explains a method for sequencing single genomes of SARS-CoV-2 and its use to explore in-host evolution drive by antibody responses, and incidence of cerebral venous thrombosis in COVID-19 patients and vaccine recipients.
In COVID-19 clinical update #59, Daniel Griffin discusses a front-line health care worker survey, pre-exposure seropositivity and subsequent infection in healthy young adults, fitted filtration efficiency of double masking, BinaxNow rapid in-home antigen test, postvaccination infections in a nursing facility, safety of mRNA vaccine in pregnant women, case control study of Bamlanivimab, no evidence for brain infection in patients with neurolgical symptoms, and mortality among US patients hospitalized with COVID-19.
Team TWiV explains how alphaviruses like Western equine encephalitis virus cross into the brain from capillaries by caveolin-mediated transcytosis, and reveal scientists’ incentives and attitudes towards public communication.
In COVID-19 clinical update #58, Daniel Griffin provides the latest update on the J&J vaccine pause, healthcare worker deaths, children and COVID, physical inactivity associated with higher risk, using monoclonal antibodies for prophylaxis, and shows us how to properly wear a face mask.
The TWiVsters explain how the shape of pleomorphic virus particles – spherical or filamentous – determines the probability of virus attachment and fusion, and resistance to selective pressure such as antibodies that block cell entry.
TWiV reviews a drug screen for inhibitors of syncytium formation, the fusing of cells caused by SARS-CoV-2, which reveals that the process is regulated by a calcium-activated ion channel and scramblase that is inhibited by the anti-parasite drug Niclosamide.
In COVID-19 clinical update #57, Daniel Griffin covers children and MIS-C, school opening plans, transmission event with masks, fomite transmission, diagnostic test performance, AZ vaccine and blood clots, and long COVID and the effect of vaccines.
The Guardians of the TWiV-o-verse discuss the process of codon deoptimization for the production of experimental infectious attenuated viral vaccines, and how a respiratory syncytial virus with 619 base changes was rescued by genomes with very large internal deletions.
Arturo Casadevall joins TWiV to discuss the use of convalescent plasma to treat COVID-19, including a history of the process, how plasma is prepared and tested, why it is difficult to conduct randomized clinical trials, how this treatment has fared and his hopes for the future.
In COVID-19 clinical update #56, Daniel Griffin notes increasing hospitalization in children and young adults, Pfizer vaccine efficacy results in 12-15 year olds, rapid self administered nucleic acid and antigen tests, mRNA vaccine efficacy in real world conditions, and improvement of long COVID after vaccination.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Brianne Barker, Ph.D.
Rich Condit, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.
Kathy Spindler, Ph.D.